Tissue Regenix Group Full Year 2023 Earnings: EPS Misses Expectations

Tissue Regenix Group (LON:TRX) Full Year 2023 Results

Key Financial Results

• Revenue: US$29.5m (up 21% from FY 2022).
• Net loss: US$1.71m (loss narrowed by 36% from FY 2022).
• US$0.024 loss per share (improved from US$0.038 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tissue Regenix Group EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 25%.

The primary driver behind last 12 months revenue was the Biorinse segment contributing a total revenue of US$20.1m (68% of total revenue). Notably, cost of sales worth US$15.5m amounted to 52% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$14.4m (92% of total expenses). Explore how TRX's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 23% growth forecast for the Biotechs industry in the United Kingdom.

Performance of the British Biotechs industry.

The company's shares are down 7.3% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Tissue Regenix Group has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.